Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 studyArmando Santoro, Camillo Porta, Stefania Salvagni et al.|The Lancet Oncology|2012Cited by 550
Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung CancerLecia V. Sequist, Joan H. Schiller, Joachim von Pawel et al.|Journal of Clinical Oncology|2011Cited by 379